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Cervical cancer is the third most common cancer in women
worldwide, after cancers of the breast and large bowel, with
approximately 470000 new cases a year in 2000, some 10% of all
cancers in women (Ferlay et al, 2001). Approximately 80% of all
cases occur in developing countries, where cervical cancer is often
the most common cancer in women, whereas in developed
countries, cervical cancer only accounts for about 5% of all
cancers in women. It has been known for 30 years from
observational data that cervical cancer is likely to have an
infectious component (Beral, 1974), subsequently confirmed as
HPV (Bosch et al, 1994). Trials of vaccination already appear
promising for primary prevention (Gravitt and Shah, 2005; Mao
et al, 2006).
In England and Wales, the age-standardised incidence of
cervical cancer in the 1970s and 1980s remained between 14 and
16 per 100000, although age-specific rates were influenced by
strong cohort effects (those women born in the 1890s were at high
risk, those born in the mid-1930s at low risk). The cervical
screening programme began in the 1960s, offering cervical smear
tests to detect premalignant lesions in women aged 25–64 years on
a 5-yearly basis, but it was largely ineffective until the late 1980s
(Murphy et al, 1988). In 1988, a national call and re-call system was
established and coverage rose rapidly to approximately 85%
(Quinn et al, 1999). As a result of these improvements, the
incidence of invasive malignancy fell continuously after 1990 to
below 9 per 100000 in 2000 (Quinn et al, 2001; Office for National
Statistics, 2003a).
Mortality from cervical cancer in England and Wales had been
declining steadily at approximately 1.5% each year from the early
1950s to the late 1980s. This long-term decline began before the
introduction of screening. From 1990, the rate of decline in
mortality increased three-fold, and by 2002 the age-standardised
death rate had fallen to 29 per 100000, barely one-third of the
death rate in 1971 (83 per 100000) (Office for National Statistics,
1999, 2003b). Only 1000 deaths were attributed to cervical cancer
in 2002, and the screening programme has been credited
with preventing 800 or more deaths a year (Quinn et al, 1999;
Peto et al, 2004).
We analysed the data for 44090 women diagnosed with
invasive cancer of the uterine cervix in England and Wales during
the 14-year period 1986–1999, some 90% of those eligible for
inclusion in the analyses. Approximately 4% of women otherwise
eligible for analysis were excluded with zero recorded survival
(date of diagnosis same as date of death). The proportion of
women for whom recorded survival was zero did not vary
between socioeconomic groups, however, and it was stable
throughout the 1990s (data not shown). Therefore, these
exclusions are unlikely to have had any substantial impact
on socioeconomic gradients in survival, or on trends in the
gradient. A further 3% of women with cervical cancer were
excluded because it was not their first primary malignancy, and 2%
because their vital status was unknown on 5 November 2002, the
date when the data were extracted for analysis.
Some two-thirds (67%) of cervical cancers were squamous
carcinomas, and a further 16% were adenocarcinomas: both
proportions were similar throughout the 1990s. Other morpholo-
gical types were individually rare, but cancers with poorly specified
morphology accounted for about 10%.
Annual incidence rates for invasive cervical cancer in the late
1990s were 50% higher among the most deprived women (12.8 per
100000) than among the most affluent (8.5 per 100000), but this
difference was less marked than in the early 1990s (63%). This is
because incidence declined more among the most deprived women
over this period (18%) than among the most affluent (11%)
(Figure 1).
SURVIVAL TRENDS
Survival from cervical cancer is moderate: in the early 1970s,
1-year relative survival was 75% and 5-year survival just over 50%
(Coleman et al, 1999). During the 1970s and 1980s, 1-year survival
improved by more than 2% every 5 years, reaching 83% for women
diagnosed during 1986–1990. Five-year survival improved more
rapidly, by more than 3% every 5 years, to reach 64% by the same
period.
In the 1990s, by contrast, 1-year and 5-year survival did
not increase significantly, remaining at 85.5 and 65.5%,
respectively (Table 1, Figure 2). The small average increase in
1-year survival (0.5% every 5 years) is adjusted for the
*Correspondence: Professor MP Coleman;
E-mail: michel.coleman@lshtm.ac.uk
British Journal of Cancer (2008) 99, S59–S62
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $32.00
www.bjcancer.comdeprivation gap in survival and for changes in the distribution
of patients by deprivation category (see above). It is a more
reliable estimate of trend than would appear from the
unchanging estimates of 83.5% in successive calendar periods,
although the rate of increase in survival is not statistically
significant.
Short-term predictions of survival up to 10 years after
diagnosis, based on hybrid analysis of patients’ survival experience
during 2000–2001 (Brenner and Rachet, 2004) suggest
that improvement in survival in the near future is unlikely
(Table 1); this reflects the lack of recent improvements in early
survival.
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Figure 1 Trends in the age-standardised incidence of cervical cancer
in women aged 15–99 years, by deprivation group: England and
Wales, 1986–1999.
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Figure 2 Relative survival (%) up to 10 years after diagnosis by calendar
period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001. Survival estimated with
cohort or complete approach (1986–1990, 1991–1995, 1996–1999) or
hybrid approach (2000–2001) (See Rachet et al, 2008).
Table 1 Trends in relative survival (%) by time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Women 83.5 (82.9, 84.0) 83.5 (82.9, 84.1) 83.5 (82.7, 84.2) 0.5 ( 0.9, 1.8) 83.8 (82.7, 84.8)
5 years Women 64.5 (63.8, 65.3) 65.1 (64.2, 65.9) 65.5 (64.4, 66.6) 0.9 ( 1.1, 2.8) 66.0 (64.5, 67.4)
10 years Women 60.7 (59.9, 61.5) 61.4 (60.4, 62.3)  1.7 ( 5.2, 1.7) 62.6 (61.0, 64.0)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008).
Table 2 Trends in the deprivation gap in relative survival (%) by time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Women  2.8** ( 4.5,  1.1)  3.6** ( 5.5,  1.8)  3.7** ( 5.9,  1.5)  0.5 ( 1.9, 0.9)  3.6* ( 6.7,  0.4)
5 years Women  3.8** ( 6.1,  1.6)  3.1* ( 5.6,  0.7)  5.1** ( 8.4,  1.7)  0.4 ( 2.4, 1.6)  4.8* ( 9.0,  0.5)
10 years Women  5.3** ( 7.6,  2.9)  2.5 ( 5.3, 0.2) 2.7 ( 0.9, 6.4)  3.8 ( 8.2, 0.7)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in the deprivation gap in survival every
5 years, adjusted for the underlying trend in survival (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). *Po0.05; **Po0.01.
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During the 1970s and 1980s, relative survival from cervical cancer
in England and Wales was consistently some 4–8% lower for
women living in deprived areas than for those in more affluent
areas (Coleman et al, 1999). This deprivation gap did not appear to
be accounted for by differences in stage at diagnosis (Schrijvers
et al, 1995).
For women diagnosed in the late 1980s, the deprivation gap in
survival was just under 3% at 1 year after diagnosis and 4% at 5
years. The deprivation gap in 5-year survival became slightly but
significantly wider during the 1990s, reaching 4–5% for women
diagnosed during 1996–1999 (Table 2, Figure 3).
Short-term predictions of survival by socioeconomic group,
using hybrid analysis of the probabilities of survival observed
during 2000–2001, do not suggest any imminent change in the
deprivation gradient in survival (Table 2).
COMMENT
Following improvements to the cervical screening programme in
the late 1980s, the incidence of invasive cervical cancer and the
death rate both fell sharply – but survival from cervical cancer has
not improved further during the 1990s, and there is no evidence
that any increase can be expected in the near future. The
differences in survival between affluent and deprived women have
been persistent for many years.
The lack of progress in the 1990s seems difficult to explain with
the available data. If the steady improvements in survival seen in
the 1970s and 1980s did in fact continue for women diagnosed at
each stage of disease during the 1990s, then the absence of any
observed trend in overall survival (all stages of disease combined)
may have been attributable to changes in the distribution of age or
stage at diagnosis.
Carcinoma in situ of the cervix was detected increasingly often
during the 1990s in women aged 20–34 years, but not in older
women (Quinn et al, 2001). In most women, effective treatment of
carcinoma in situ would have prevented progression of the disease
to invasive cancer: in that sense, cervical screening can actually
prevent the development of invasive cancer that would otherwise
have arisen. Women with carcinoma in situ, predominantly young
women, were not included in these analyses, and the overall
survival trends for women aged 15–99 years, who were ultimately
diagnosed with invasive cancer, did not change significantly by
standardisation for age (data not shown here). Therefore, a shift
towards an older age distribution of women diagnosed with
invasive cervical cancer cannot explain the lack of improvement in
overall survival.
The spectrum of stage at diagnosis of invasive cancer may have
shifted towards more advanced cases, as a result of continuing
improvement in the screening programme. As a result, any
improvement in survival at each stage of disease may have been
somewhat masked in the overall survival figures for all women
with invasive cancer of the cervix. The need for high-quality data
on stage of diagnosis to enable adequate evaluation of national
trends in cancer survival is obvious, but those data can only be
captured by cancer registries if the relevant information is
systematically recorded in the medical record for all cancer
patients.
The decline in the incidence and mortality of invasive cervical
cancer is a very welcome result of improved cervical screening.
Primary prevention by vaccination against HPV also appears to
have great promise within the next decade. Despite this evidence of
solid progress in the control of cervical cancer, 1000 deaths a year
is still far too many for a disease that has been largely preventable
for decades. It remains a cause for concern that no significant
improvement in survival from cervical cancer has occurred since
the late 1980s, and that socioeconomic inequalities in survival have
tended to worsen rather than improve.
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